FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Highlighting the promising preliminary results of retatrutide for obesity management through a systematic review and meta-analysis, emphasizing the need for further research.
研究ライブラリに戻る
retatrutidetriple hormone receptor agonist

Highlighting the promising preliminary results of retatrutide for obesity management through a systematic review and meta-analysis, emphasizing the need for further research.

May 16, 2026
Share

元の論文

Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.

Tewari Jay et al.Expert review of clinical pharmacology2025
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、上記の元の論文から得られた見解をペプチド研究コミュニティ向けに読みやすく分解しています。私たちの目標は、最も重要な点 — 実践的な意味合い、証拠の強さ、そして継続的研究に対する影響 — を強調することです。

Novel Triple Hormone Receptor Agonist Shows Promise in Obesity Management

Published: May 16, 2026 | Source: Expert review of clinical pharmacology (2025) | Category: retatrutide, triple hormone receptor agonist

Overview

A recent systematic review and meta-analysis published in Expert Review of Clinical Pharmacology highlights the potential of retatrutide, a novel triple hormone receptor agonist, for managing obesity. The study synthesizes data from four randomized controlled trials (RCTs) and suggests that retatrutide is more effective than placebo in reducing obesity-related outcomes, with minimal safety concerns.

Study Background

Obesity management has long been a challenge due to the complexity of metabolic pathways involved. Retatrutide, by targeting multiple hormone receptors simultaneously, offers a promising approach to weight loss. This meta-analysis aimed to consolidate existing evidence on retatrutide's efficacy and safety profile, providing insights for both researchers and clinicians.

What the Research Found

The systematic review included four RCTs that compared retatrutide with placebo in managing obesity. The analysis revealed a dose-dependent relationship between retatrutide dosage and weight loss outcomes. Specifically, participants receiving 12 mg of retatrutide experienced the most significant reductions in body mass index (BMI) and waist circumference compared to those on lower doses or placebo.

In terms of safety, no major adverse events were reported with retatrutide use, indicating a comparable safety profile to the control group. This suggests that retatrutide may be well-tolerated by patients undergoing obesity management treatments.

What This Means for Peptide Users

While these findings are encouraging, it is important to note that retatrutide is still in its early stages of clinical development. The current data supports further investigation into this peptide's potential benefits and long-term safety profile. For individuals considering the use of peptides like retatrutide, consulting with a healthcare provider remains crucial.

Limitations and Caveats

The study’s reliance on only four RCTs limits the generalizability of its findings. Additionally, the lack of longer-term data means that potential side effects or benefits over extended periods remain unknown. These limitations underscore the need for larger, more comprehensive clinical trials to validate retatrutide's efficacy and safety.

How This Compares to Previous Research

Previous studies on single hormone receptor agonists have shown mixed results in terms of both efficacy and safety. Retatrutide’s multi-receptor approach appears to offer a promising alternative by potentially enhancing therapeutic effects while maintaining a favorable safety profile. However, direct comparisons with other peptides are limited due to the novelty of retatrutide.

Our Analysis

PeptideVault's analysis suggests that this meta-analysis provides valuable preliminary evidence supporting retatrutide’s potential as an obesity management tool. The study adheres to rigorous methodologies and presents clear findings regarding efficacy and safety. Nonetheless, the need for further research is evident to address current limitations and provide a more robust understanding of retatrutide's long-term effects.

Key Takeaways

  • Retatrutide shows promise in reducing obesity-related outcomes compared to placebo.
  • A dose-dependent relationship exists between retatrutide dosage and efficacy.
  • Current safety data suggests that retatrutide is well-tolerated, but more research is needed for comprehensive understanding.
  • Consultation with healthcare providers remains essential for individuals considering peptide therapy.

Original Source

Citation: Tewari Jay, Qidwai Khalid Ahmad, Tewari Ajoy et al. (2025). Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.. Expert review of clinical pharmacology. DOI: 10.1080/17512433.2025.2450254

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

編集者の注

この分析はPeptide Contacts研究チームによって作成されました。情報確認のために常に元のソースをご確認ください。 元の論文 詳細な方法論とデータについては 元の出版物は以下で利用可能です PubMed.

関連研究

Comments

Sign in to join the discussion

この分析は査読済みの研究から生成され、教育目的のみで使用されます。医療アドバイスにはなりません。ペプチドベースの治療を使用する前に常に格付けされた医療専門家に相談してください。